| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 19 |
| 1 | CYCLOPHOSPHAMIDE | 14 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 14 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 14 |
| 4 | METHOTREXATE SODIUM | 13 |
| 5 | METHOTREXATE | 12 |
| 6 | PREDNISONE | 11 |
| 7 | CYTARABINE | 10 |
| 8 | ETOPOSIDE | 9 |
| 9 | FLUDARABINE PHOSPHATE | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | MITOXANTRONE HYDROCHLORIDE | 3 | 0.0005 |
| 1 | BENDAMUSTINE HCL | 3 | 0.0002 |
| 2 | CYTARABINE | 10 | 0.0002 |
| 3 | FLUDARABINE PHOSPHATE | 6 | 0.0002 |
| 4 | ETOPOSIDE | 9 | 0.0001 |
| 5 | VINCRISTINE SULFATE | 3 | 0.0001 |
| 6 | DASPONE | 1 | 0.0001 |
| 7 | DAPSONE GEL, 5% | 1 | 0.0001 |
| 8 | DAPSONE | 1 | 0.0001 |
| 9 | RITUXIMAB | 19 | 0.0001 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 20 |
| 1 | Alkylating Drug [EPC] | 14 |
| 2 | Corticosteroid [EPC] | 14 |
| 3 | Folate Analog Metabolic Inhibitor [EPC] | 12 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 10 |
| 5 | Topoisomerase Inhibitor [EPC] | 9 |
| 6 | Platinum-based Drug [EPC] | 3 |
| 7 | Sulfone [EPC] | 1 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Topoisomerase Inhibitor [EPC] | 9 | 0.0001 |
| 1 | Sulfone [EPC] | 1 | 0.0001 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 20 | 0.0001 |
| 3 | Alkylating Drug [EPC] | 14 | 0.0001 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 10 | 0.0000 |
| 5 | Folate Analog Metabolic Inhibitor [EPC] | 12 | 0.0000 |
| 6 | Platinum-based Drug [EPC] | 3 | 0.0000 |
| 7 | Corticosteroid [EPC] | 14 | 0.0000 |